Cost-Effectiveness of Abemaciclib in Early Breast Cancer Patients: One Size Fits All or Tailoring to Patients’ Needs?

PURPOSE: The addition of two years of abemaciclib treatment to standard adjuvant endocrine therapy in all patients with high risk ER+, HER2- early breast cancer (EBC) has been approved by the US Food and Drug Administration (FDA). Pre-selection of patients with an immediate risk of recurrence within...

Descripción completa

Detalles Bibliográficos
Autores principales: Jongbloed, Elisabeth M, Blommestein, Hedwig M, van Schoubroeck, Hannah M, Martens, John W M, Wilting, Saskia M, Uyl-de Groot, Carin A, Jager, Agnes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9940501/
https://www.ncbi.nlm.nih.gov/pubmed/36814469
http://dx.doi.org/10.2147/BCTT.S387375

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9940501/
https://www.ncbi.nlm.nih.gov/pubmed/36814469
http://dx.doi.org/10.2147/BCTT.S387375

Ejemplares similares